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Abstract
Purpose Patients with primary immunodeficiency diseases
(PIDD) may present with recurrent infections affecting different
organs, organ-specific inflammation/autoimmunity, and also in-
creased cancer risk, particularly hematopoieticmalignancies. The
diversity of PIDD and the wide age range over which these
clinical occurrences become apparent often make the identifica-
tion of patients difficult for physicians other than immunologists.
The aim of this report is to develop a tool for educative programs
targeted to specialists and applied by clinical immunologists.
Methods Considering the data from national surveys and
clinical reports of experiences with specific PIDD patients,
an evidence-based list of symptoms, signs, and corresponding
laboratory tests were elaborated to help physicians other than
immunologists look for PIDD.
Results Tables including main clinical manifestations, re-
stricted immunological evaluation, and possible related diag-
nosis were organized for general practitioners and 5 special-
ties. Tables include information on specific warning signs of
PIDD for pulmonologists, gastroenterologists, dermatologists,
hematologists, and infectious disease specialists.
Conclusions This report provides clinical immunologists with
an instrument they can use to introduce specialists in other
areas of medicine to the warning signs of PIDD and increase
early diagnosis. Educational programs should be developed
attending the needs of each specialty.
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Abbreviations
ALPS Autoimmune lymphoproliferative syndrome
ANA Antinuclear antibodies
AP50 Alternative pathway of complement system
APECED Autoimmune polyendocrinopathy-
candidiasis-ectodermal dystrophy
C1INH C1 esterase inhibitor
CBC Complete blood count
CD40L CD40 ligand (L) deficiency
CGD Chronic granulomatous disease
CSR Class switch recombination
CVID Common variable immunodeficiency
DHR Dihydrorhodamine
EBNA Epstein-Barr nuclear antigen






OPV Oral poliovirus vaccine
RCP Reactive C protein
SCID Severe combined immunodeficiency
SLE Systemic lupus erythematosus
TSH Thyroid-stimulating hormone
WAS Wiskott-Aldrich syndrome
WHIM Warts, hypogammaglobulinemia, infections,
and myelokathexis syndrome
XLA X-linked agammaglobulinemia
XLP X-linked lymphoproliferative syndrome
Introduction
Primary immunodeficiency diseases (PIDD) are a heteroge-
neous group of more than 150 disorders that result frommany
different congenital, or even acquired, genetic defects affect-
ing the innate and adaptive immune systems [1, 2]. Despite
major advances over the last 20 years in the clinical and
molecular characterization of PIDD, many patients remain
undiagnosed or have a substantially delayed diagnosis with
adverse results on morbidity and mortality.
The diagnosis of PIDD is most often suggested by recur-
rent or unusual infections and inflammatory or autoimmune
conditions. Several lists of warning signs for children or adults
are based on these main clinical presentations and, in some
cases, family history [3–6]. Arkwright and Gennery
concluded that the 10 warning signs promoted by the Jeffrey
Modell Foundation have a sensitivity of 56% and a specificity
of 16 % [7]. Subbarayan et al. evaluated 563 children and
concluded that the strongest identifier of PIDD is family
history. Of secondary relevance were the use of intravenous
antibiotics for sepsis, and failure to thrive in children with T
lymphocyte primary immunodeficiency disease [8]. Mehra
et al. observed that 20 % of hospitalized patients with
suspected immune defects would not be included for immu-
nologic investigation according to the 10 warning signs [9].
All currently available lists of warning signs are based on
family history and descriptions of infections suggestive of an
immunodeficiency. These are general signs that should be
known by all physicians. However, there are many specific
warning signs that certain specialists need to be aware of.
Because of the diversity of immune defects, their respective
clinical presentations, and the difficulties in reaching many
non-immunology subspecialists with these general warning
signs, many signs that should raise suspicion of PIDD are
missed by physicians and a large proportion of patients are not
properly diagnosed [10–12].
Here, we provide lists of specific warning signs in tables
that can be used to familiarize subspecialists with signs and
symptoms of PIDD that they are likely to see in patients
referred to their practices. The tables will provide quick sum-
maries of the many warning signs and diagnoses encountered
by different specialists, with suggestions for appropriate
screenings, immunological evaluations, and proper referrals
to clinical immunologists.
Methods
The information offered in this article is based on a review of
the pertinent literature and the clinical experience of all au-
thors. Tables I and II list the tests that are recommended for
screening of the main immunologic functions, along with
histories and infections that all physicians and health care
workers need to recognize as warning signs of a possible
immunodeficiency. Subsequent tables list special clinical pre-
sentations that should alert specific groups of specialists.
When presenting information about PIDD from this article,
it is important to always include Tables I and II, and the
pertinent tables prepared for various specialties.
General Screening and Evaluation
Table I lists the tests that should be performed according to the
main clinical presentations specified in the subsequent tables.
In some situations the relevant evaluation is not part of gen-
erally available screening tests, and it is preferable to refer the
patient directly to an immunologist so that routine and spe-
cialized tests can be performed simultaneously. The tables for
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specialists will provide data for further laboratory
investigation.
Recurrent, Severe, or Unusual Infections
Our recommendations are similar to those in published lists of
warning signs that consider the frequency of various types of
infections. However, it is also important to consider the infec-
tion type, the circumstances under which infections occur, and
which organs and tissues they affect. In our experience, this is
a more effective way to identify PIDD than emphasizing exact
numbers of different infections or special definitions of sever-
ity. When severity is considered, it is important to consider the
pathogenicity of an infectious agent; infections with any path-
ogen of low pathogenicity, such as atypical mycobacteria or
toxoplasma, are suggestive of an immune defect even if the
infection is not severe. Epidemiological data about infectious
agents should be considered as well. For example,
paracoccidioidomycosis should be more commonly identified
in tropical countries than in European or North American
countries (Table II). A general condition that should make
any infection suspicious is the concomitant presence of non-
infectious complications commonly associated with PIDD,
including severe allergy, autoimmunity, unregulated inflam-
mation, or malignancies.
A positive family history definitely suggests a PIDD. How-
ever, it is also important to consider certain negative family
histories—for example, a family in which only one of 4 siblings
has recurrent infections. The fact that the other 3 siblings and
parents are healthy rules out environmental factors as the factors
predisposing an individual to recurrent infections; it also high-
lights the immunopathogenic effects of genetic alterations that
may have occurred in a single family member.
Recurrent infections are often attributed to the presence of
non-immune abnormalities, such as Down syndrome, muscu-
lar dystrophy, or various congenital heart defects. Such pa-
tients may also have an immunodeficiency, and appropriate
recognition and treatment may significantly improve their
quality of life.
Infectious Diseases
Many PIDDs have unique susceptibilities to some pathogens
and/or sites of infections that are listed in Table III. Antibody-
mediated immunity needs to be evaluated in all severe or
unusual infections, in addition to other possible concurring
immunological defects. A practical point is to screen for
combined immunodeficiencies.
Infectious disease is the hallmark of PIDD, and infectious
disease specialists are the physicians most likely to encounter
patients with PIDD in their daily practice. The burden of
infectious disease is immense even in children with healthy
immune systems. Recurrent otitis media is considered to be
more than 4 episodes of acute otitis media during the past
12 months with complete resolution of the disease between
episodes [13–15].
Any patient with severe or recurrent infections or infection
by opportunistic or uncommon microorganisms must be in-
vestigated for PIDD after discarding the possibility of infec-
tion with human immunodeficiency virus (HIV).
Pyogenic encapsulated bacteria (Streptococcus
pneumoniae , Haemophilus influenzae) are frequently associ-
ated with infections in patients with antibody or complement
deficiencies. Patients with complement deficiencies may also
present with meningitis and sepsis associated with pathogens
such as Neisseria [16].
Agammaglobulinemic patients and, to a lesser extent, pa-
tients with common variable immunodeficiency (CVID) have
an increased risk of developing bloodstream bacterial infec-
tions [17]. A study of 201 patients with X-linked agamma-
globulinemia (XLA) indicated that 11 % had at least one
episode of meningitis or encephalitis, 10 % had at least one
episode of sepsis, and 8 % had at least one episode of septic
arthritis [18]. Patients with XLA or CVID are at an increased
risk for severe and often fatal infections with enteroviruses,
Table I Screening laboratory tests for the non-immunology specialist in
order to detect patients with possible PIDD
Possible PIDD Screening Tests
Antibody mediated
immunity (AMI)
• CBC and differential
• Serum IgG, IgA, IgM




• CBC and differential
• Lymphocytes: CD3, CD4, and CD8;
CD19; CD16/56
• Chest x-ray
Complement (C) • C4 (if angioedema without urticaria)
• CH50
Phagocytosis (P) • Neutrophil counts
Neutropenia • Oxidative burst by DHR test
Neutrophil function
Autoimmunity • ANA, RCP
Innate immunity (II) • Specialized tests (consult an
immunologist)
The screening lab tests should be part of any initial immune evaluation.
Only the abbreviations in parentheses will be listed as suggested screen-
ing tests in all subsequent tables. HIV testing should be a routine test to
exclude AIDS
Abbreviations : ANA antinuclear antibodies, CBC complete blood count,
DHR dihydrorhodamine, RCP reactive C protein
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including echoviruses, polioviruses, and coxsackie viruses
[17]. The central nervous system is nearly always involved
in these infections, and evidence of systemic involvement of
muscle, liver, and/or joints is present in about 40% of patients.
These infections are associated with high mortality and mor-
bidity [19].
Other organisms, including Staphylococcus aureus ,
Pseudomonas spp, Mycoplasma spp, Enterobacteria-
ceae, Campylobacter spp, Giardia , and enteroviruses,
may be isolated from patients with specific types of PIDD
[17]. Infections caused by Serratia marcessens , Nocardia
spp, Chrombacterium violaceum ,Granulobacter bethesdensis ,
Burholderia cepacia , and gladioli are strongly suggestive
of chronic granulomatous disease (CGD). Evaluation of
259 patients with the X-linked recessive form of CGD
indicated that 21 % had a history of either bacteremia or
fungemia [20].
Infections caused bymycobacteria, Salmonella , Leishman-
ia , and Cryptococcus suggest defects in the interferon-γ/
interleukin-12 axis included in innate immunity (Table III)
[21]. As previously mentioned, the incidence of certain in-
fectious agents must be considered according to their ende-
micity in particular geographical regions. Side effects of
Bacillus Calmette-Guérin (BCG) occur in more than 50 %
of the severe combined immunodeficiency (SCID) patients in
Brazil and more than 17 % of CGD patients in Latin America;
this is a relevant warning sign for PIDD [22]. Adverse reac-
tions to other live attenuated viral vaccines such as poliovirus
Table II Infections that are general warning signs of PIDD for all
clinicians
Otitis media*
• Early onset <3–4 months of age
• Recurrence after antibiotic treatment
• Complications: mastoiditis
• Association with invasive infections
• Recurrence after ear tubes
• Change to sinusitis after ear tubes
• Repeated ear tube placement
* The number of otitis episodes that suggest PIDD varies with age:
≥ 3 episodes/year under 5 years; ≥ 2 episodes/year ≥5 years
Chronic recurrent rhinosinusitis
• Association with persistent asthma
• Requirement for sinus surgery due to fungal infections
Pneumonia
Evaluate after a single pneumonia if the patient has:
• A personal history of recurrent upper respiratory infections
(URI) including recurrent otitis media
• A personal history of other immune problems (autoimmunity,
chronic diarrhea, periodic fevers, persistent skin rash, etc.)
• Pneumonia that requires hospitalization (any: ICU or regular service)
• Persistent pneumonia after adequate therapy with antibiotics




Evaluate patients with 2 or more pneumonias:
• All patients (preferred option)
Or evaluate only if:
• X-ray proven pneumonias in different lung sites
• Positive family history for early death or primary
immunodeficiency (PIDD)
• Pneumonia that is complicated by pneumatocele or
bronchiectasis









* More relevant signs in developed countries or non-endemic
countries for these diseases
Chronic diarrhea or colitis











Recurrent or persistent candidiasis or fungal infections
Abscesses (liver, lungs, cutaneous)
Staphylococcus aureus




Complications due to live attenuated vaccines
Disseminated BCG (Mycobacterium bovis Bacillus Calmette-Guérin)
Poliomyelitis due to poliovirus vaccine
Diarrhea due to rotavirus vaccine
See text under “Recurrent, Severe, or Unusual Infections”
For all the common infections listed in this table, evaluation starts with a
complete blood count to rule out neutropenia and assessment of antibody
mediated immunity
l ti
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and rotavirus should be carefully observed as well [23]. Sev-
eral developing countries maintain campaigns with Sabin
immunization with the possibility to cause vaccine-derived
disease [24].
Although the respiratory and gastrointestinal tracts are the
most common systems for presenting illness, the authors ob-
served lymphadenopathy as the most common manifestation
in the group of combined T and B cell immunodeficiencies,
Table III Warning signs of PIDD for infectious disease specialists
Clinical occurrences PIDD Lab screening tests
Infections from extracellular bacteria Antibody deficiencies AMI
Complement deficiencies C, ANA
Neutropenias P
IRAK-4, MyD88 II, RCP
Infections due to Neisseria meningitidis Complement deficiency of terminal
components (Membrane attack complex)
C + AP50
Infection from S aureus, and gram-negative
bacterias: Serratia marcescens, Burkholderia
cepacia and gladioli ,Nocardia spp ,
Chromobacterium violaceum , Granulobacter
bethesdensis.
Chronic granulomatous disease (CGD) P
Hyper IgE syndrome (HIES)
Features: pneumonia from S aureus ,




Infection from fungi: Pneumocystis jiroveci;
Aspergillus and Candida albicans.
T cell defects CMI
CD40 ligand (L) deficiency AMI
HIES Serum IgE, eosinophilia
Specific Scorea
CGD P
Infection from Candida albicans Chronic mucocutaneous candidiasis CMI + T lymphocyte proliferation
induced by Candida
Infection by atypical Mycobacteria /Salmonella
and/or Bacillus Calmette-Guérin side effects;
Paracoccidioides sp, Leishmania, Cryptococcus
T cell deficiencies CMI
Severe combined immunodeficiency (SCID) AMI + CMI
Mendelian susceptibility to mycobacterial diseases P and/or II
Infections from Herpes T and NK cell deficiencies CMI
Fulminant or chronic infection by Epstein-Barr virus Familial hemophagocytic lymphohistiocytosis
(FHL) syndrome
X-linked lymphoproliferative (XLP) syndromes,
types 1 or 2
CBC, triglycerides, ferritin,
serology EBNA
Recurrent or persistent Cryptosporidium, Isospora CD40L deficiency AMI
Common variable immunodeficiency (CVID) AMI
Giardiasis Antibody deficiencies AMI
Complications due to BCG , rotavirus or Varicella
vaccines
SCID, CGD CMI and/or II and/or P
Complications due to oral polio vaccine Antibody deficiencies AMI
Persistent fever of unknown origin Autoinflammatory diseases ANA, RCP, blood smear
Abbreviations : AMI antibody mediated immunity, ANA antinuclear antibodies, CBC complete blood count, CMI cellular mediated immunity, EBNA
Epstein-Barr nuclear antigen, II innate immunity, P phagocytosis, RCP reactive C protein
a Score for classical hyper IgE diagnosis [26]
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and superficial abscesses and lymphadenopathy in the group
of congenital defects of phagocyte number and/or function
[22, 25, 26] (Table III).
Otorhinolaryngology and Pulmonology
High percentages of pediatric and adult patients with
PIDD have upper and/or lower respiratory tract bacterial
infections; thus, they may be referred to otorhinolaryn-
gologists or pulmonologists. Rezaei reported on 930
patients with PIDD, 353 cases of which were identified
in the last 5 years. The most common presenting feature
of PIDD was pneumonia, which was seen in 20.1 % of
patients, followed by diarrhea (13.7 %), sinusitis
(10.3 %), and otitis media (9.6 %) [27]. It is important
to rule out the existence of cofactors that might be
associated with upper respiratory infections (e.g.,
smoking, day care attendance, gastroesophageal reflux,
allergy) before performing extensive immunological
evaluation. The most common of these infections are
recurrent otitis media, chronic sinusitis, and pneumonia.
Recurrent sinus infections have been reported as a pre-
senting occurrence in 19 % to 98 % of patients with
PIDD (wide range reflects the variety of PIDD) [28,
29]. An assessment of 103 pediatric and adult patients
with a history of recurrent or chronic ear, nose, or
throat infections indicated that 16.5 % had defects in
antibody-mediated immunity: CVID (n =2), IgA defi-
ciency (n =4), IgG subclass deficiency (n =3), and spe-
cific antibody deficiency against polysaccharide antigens
(n =8) [30]. Warning signs for patients with recurrent
otitis include progressive infections leading to mastoiditis;
associated abscesses or systemic infections; lack of respon-
siveness to adequate antibiotic treatment; or occurrence of
unusual, severe, or frequently relapsing infections in other
sites [31] (Table II).
Pneumonia is a common infectious manifestation of
PIDD; one study of patients with CVID indicated that at
least two-thirds had one or more pneumonia diagnoses
prior to diagnosis of PIDD [32]. According to some
registries [33, 34], approximately 50 % of patients with
humoral immunodeficiency suffered from upper respira-
tory tract infections, and 40 % of XLA and CVID
patients suffered from recurring pneumonia [27, 35].
Pathogens frequently associated with pneumonia in pa-
tients with antibody deficiencies include S pneumoniae ,
H influenzae type b, Haemophilus parainfluenzae ,
Mycoplasma spp, Pseudomonas spp, and Staphylococ-
cus spp [17]. Patients with cellular deficiencies such
as CD40 Ligand (CD40L) deficiency present with
pneumonia that is a result of opportunistic pathogens
such as Pneumocystis , fungal, or viral infections [36]
(Table IV).
Several observational studies have indicated that compli-
cations and sequelae of infectious diseases such as bronchiec-
tasis (76 %), recurrent chest infections (21 %), and granulo-
matous lung disease (5%) should also raise suspicion of PIDD
[37]. A systematic review of the literature conducted byWood
et al. included results from 7 surveys showing that respiratory/
chest infections were presenting symptoms for 37 % to 90 %
of patients with PIDD [29]. Touw et al. reviewed 26 studies
that included 587 patients with CVID and found that up to
73 % developed chronic structural pulmonary complica-
tions—most often bronchiectasis and bronchial wall thicken-
ing [38]. In another study, pulmonary imaging by chest com-
puted tomography in 30 patients with PIDD revealed abnor-
malities in 53 %; among these were bronchiectasis (75 %),
peribronchial thickening (19 %), air trapping (31 %), lung
volume reduction (25 %), atelectasis (12 %), follicular bron-
chiolitis (12 %), ground-glass abnormality (12 %), and paren-
chyma nodules (6 %). In this study, pulmonary function
testing also indicated abnormalities in 18 patients; these in-
cluded an obstructive (38.8 %), restrictive (44.4 %), or mixed
(16.7 %) pattern of lung function abnormalities [39].
Results from other studies have indicated that Staph-
ylococcus -associated pneumonia and bronchial aspergillosis
[40] are seen in CGD; lung abscesses represent usual charac-
teristics in hyper IgE syndrome (HIES); and interstitial pneu-
monia may be observed in patients with SCID [41] (Table IV).
Gastroenterology
Frequent gastrointestinal manifestations are malabsorption,
diarrhea, hepatomegaly, and inflammatory bowel disease
(IBD) and all of these are commonly associated with increased
morbidity [42–44]. In a systematic review, Wood et al. indi-
cated that GI infections were a presenting symptom in 6 % to
19 % of patients with PIDD [29]. Severe diarrhea can start
early in life in patients with SCID or immunodysregulation,
polyendocrinopathy, and enteropathy, X-linked (IPEX); both
of these PIDD are considered pediatric emergencies [45–47].
Rezei et al., in their study of 930 patients with PIDD, indicated
that infectious diarrhea occurred in 40.4 % of patients [27].
Recurrent or chronic giardiasis is suggestive of an underlying
antibody deficiency [17]. Other pathogens in patients
with infectious colitis include rotavirus, Campylobacter,
enteroviruses, Cryptosporidium parvum , Salmonella
spp, and Clostridium difficile [18]. Liver abscesses
caused mainly by S aureus may also be seen in patients
with CGD and HIES (Table V).
Results from a study focusing mainly on pediatric patients
with PIDD indicated clinical evidence of liver disease, includ-
ing hepatomegaly, in 35.5 %; 8 patients (13 %) had clinical
and/or laboratory evidence of chronic liver disease.
Hepatobiliary infection, sclerosing cholangitis, nodular
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regenerative hyperplasia, and portal hypertension are frequent
conditions in CD40L deficiency [48, 49].
Rheumatology
The risk for autoimmune diseases is elevated in patients with
PIDD and is sometimes the only clinical manifestation of their
causative condition. Results from a larger study of 248 pa-
tients with CVID indicated that 69 (27.8 %) had autoimmune
disease. The most common conditions were thrombocytope-
nia in 18 patients, hemolytic anemia in 12, rheumatoid arthri-
tis in 5, and juvenile rheumatoid arthritis in 4 [50, 51]. Results
from another study of 189 patients with systemic lupus ery-
thematosus (SLE) indicated that 6 % had IgA deficiency [52].
Other PIDD are the result of genetic defects that lead to
immune dysregulation associated with autoimmune occur-
rences. Patients with autoimmune lymphoproliferative syn-
drome (ALPS) develop generalized lymphadenopathy,
hepatosplenomegaly, hypergammaglobulinemia, B cell lym-
phocytosis, and autoimmune manifestations that commonly
include hemolytic anemia, glomerulonephritis, and idio-
pathic thrombocytopenic purpura [53]. Autoimmune
polyendocrinopathy, candidiasis, and ectodermal
dystrophy (APECED) are also associated with symp-
toms of autoimmune disease [54]. Patients with IPEX
have mutations in the FOXP3 gene in regulatory T
cells, which leads to severe autoimmunity with a high
mortality rate [55]. First components of complement
deficiency have also been shown to be associated with
conditions such as SLE and are likely to prompt referral
to a rheumatologist [56]. An important “red flag” for
SLE and complement defects is negative serology to
double-stranded DNA [57].
Bone and joint abnormalities can occur in patients with
PIDD. The most common of these is arthritis, which may be
associated with antibody deficiencies, and, less often, with
CGD and Wiskott-Aldrich syndrome (WAS) [58, 59]. Impor-
tantly, infections withUreaplasma urealyticum , andMycoplas-
ma ssp may lead to erosive arthritis in patients with severe
antibody deficiencies. These infections most often result in
large-joint monoarthritis involving the knee, shoulder, elbow,
or hip joints, and less often in symmetrical polyarthritis [17].
Patients with certain PIDD, such as autoinflammatory syn-
dromes, will present with generalized serositis that might be
confused with infectious arthritis. This is often accompanied
by a myriad of symptoms, including elevation of acute phase
Table IV Warning signs of PIDD for pulmonologists
Clinical occurrences PIDD Laboratory tests
Pneumonias due to extracellular
bacteria + otitis and sinusitis
Antibody deficiencies AMI
Complement deficiencies C, ANA
Pulmonary abscess
Pneumatocele
Hyper IgE syndrome (HIES)
Features: pneumonia by S aureus , eczema,




Pneumonias due to Staphylococcus
or fungi
Chronic granulomatous disease (CGD): susceptibility
to infections by catalase positive microorganisms. Other
infections: adenitis, liver abscess, osteomyelitis
P
Glucose-6-phosphate dehydrogenase (G6PD) deficiency
Myeloperoxidase deficiency (common in diabetes)
G6PD activity
Peroxidase level
HIES Serum IgE, eosinophilia
Specific Scorea
Pneumonia due to P jiroveci T cell deficiencies/CD4+ lymphopenia CMI, AMI
Lymphoproliferation assay
CD40 ligand (L) deficiency AMI, CMI
Wiskott-Aldrich syndrome (WAS), eczema +
thrombocytopenia
CBC including platelet number and size
(small sized platelets); CMI, AMI
Pneumonia due to Mycobacteria
tuberculosis or atypical mycobacteria
T cell deficiencies/CD40L deficiency CMI, AMI
Mendelian susceptibility to mycobacterial diseases II
Abbreviations : AMI antibody mediated immunity, ANA antinuclear antibodies, CBC complete blood count, CMI cellular mediated immunity, II innate
immunity, P phagocytosis
a Score for classical Hyper IgE diagnosis [26]
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reactants, rash, deafness, joint deformity, and multifocal oste-
omyelitis [60].
Dermatology
Patients with PIDD may have skin conditions including fun-
gal, bacterial, or viral infections; eczematous dermatitis;
erythroderma; skin symptoms of autoimmune diseases such
as SLE or scleroderma; vasculitis; granuloma formation; and/
or problems characteristic of specific immunodeficiency syn-
dromes (e.g., telangiectasia, gray hair, and depigmentation)
[61]. An immunological assessment of 382,383 pediatric pa-
tients admitted to an outpatient dermatology group indicated
that 130 had PIDD. Of these, 69 % had skin infections, 29 %
had eczema-dermatitis, and 44 % had other associated cuta-
neous conditions. In 79% of this cohort, cutaneous abnormal-
ities preceded and were the basis for the clinical immunologic
diagnosis [62], demonstrating the relevance and high frequen-
cy of dermatologic manifestations in PIDD patients.
Results from a cross-sectional study of 210 pediatric pa-
tients with PIDD (68 with antibody deficiencies, 22 with Tcell
and combined deficiencies, 57 with phagocytic defects, and
63 with other PIDD) indicated that 67 of the patients (31.9 %)
had cutaneous abnormalities preceding the diagnosis of PIDD.
Overall, 99 patients had infections and 27 had eczematous
dermatitis [63].
Candida infections that may be among the first signs of PIDD
include mucocutaneous candidiasis,Candida paronychia , gran-
uloma formation, and erythroderma [64]. Patients with phago-
cytic, cellular, combined, and other PIDD exhibit immune def-
icits that confer increased susceptibility to fungal infections.
Infections associated withCandida ,Aspergillus ,Cryptococcus ,
Histoplasma , Paecilomyces , Scedosporium , Trichosporon ,
Penicillium , and other fungal organisms have been observed
in patients with CGD, SCID, HIES, defects in the interferon-γ/
interleukin-12 axis, DiGeorge syndrome/22q deletion syn-
drome, CD40L deficiency, WAS, and CVID [64]. Patients with
Chediak-Higashi or Griscelli syndromes present partial albinism
Table V Warning signs of PIDD for gastroenterologists
Clinical occurrences PIDD Laboratory tests
Chronic diarrhea Antibody deficiencies AMI
Inflammatory bowel disease Combined immunodeficiencies (infants) CMI, AMI
Chronic giardiasis
Autoimmune enteropathy + severe intractable
diarrhea. Other diagnoses associated:
hypothyroidism, eczema, thrombocytopenia,
autoimmune hemolytic anemia, neonatal diabetes
Immunodysregulation, polyendocrinopathy
and enteropathy, X-linked (IPEX)
CMI, Coombs, glycemia, and TSH
ANA
Persistent candidiasis Combined immunodeficiencies CMI
T cell Lymphoproliferative assay





ANA and endocrine evaluation
Severe abdominal pain emulating an acute abdomen Hereditary angioedema Dosage and/or functional activity
assay of C1INH, C4, C1q
Liver abscess mainly due to S aureus Chronic granulomatous disease (CGD) P
Hyper IgE syndrome (HIES) Serum IgE, eosinophilia
Specific Scorea
Hepatobiliary infection due to C parvum CD40 ligand (L) deficiency AMI
Inflammatory bowel disease in infants CGD P
Interleukin-10 (IL-10) or interleukin
10 receptor (IL-10R) deficiencies
II
Abbreviations : AMI antibody mediated immunity, ANA antinuclear antibodies, C1INH C1 esterase inhibitor, CMI cellular mediated immunity,
CBCcomplete blood count, II innate immunity, P phagocytosis, TSH thyroid stimulating hormone
a Score for classical Hyper IgE diagnosis [26]
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and gray hair; dermatologists are frequently the first consulted
specialists [65]. Prompt diagnosis is established by demonstra-
tion of giant intracellular granules in eosinophils, basophils, and
monocytes, and are pathognomonic of this disease [66].
Eczema and high serum IgE levels in the first months of life
frequently lead to referral to allergists due to suspicion of cow
milk protein allergy. However, these occurrences are also
present in patients with hypomorphic SCID, IPEX, WAS,
DOCK8, and HIES [67]; it has been shown that differential
diagnosis is crucial for prognosis [68]. Zhang et al. described
DOCK8 mutations in patients with a variant of combined
immunodeficiency characterized by unusual susceptibility to
cutaneous viral infections and cancers. In addition, DOCK8
deficiency was found in a subgroup of patients who were
previously thought to have autosomal recessive HIES with
severe allergic manifestations [69]. These syndromes exem-
plify the need for improved knowledge of PIDD for derma-
tologists (Table VI). In addition, angioedema without urticaria
is often referred to both allergists and dermatologists. Family
histories are helpful for such cases, and C4 levels could be a
useful screening test [70].
Hematology/Oncology
Autoimmune hemolytic anemia, thrombocytopenia, and/or
neutropenia are also seen in patients with selective IgA defi-
ciency, CVID, and class switch recombination (CSR) defects
[50, 71]. In some patients, hematologic abnormalities reflect
the underlying pathology responsible for the immunodeficien-
cy. Wiskott-Aldrich syndrome is associated with defects in
both B-lymphocyte and T-lymphocyte function, and these
patients also have intrinsic platelet abnormalities and signifi-
cant thrombocytopenia with small platelets [71]. In addition
to congenital neutropenia, neutropenia is also associated
with XLA, CD40L deficiency, CVID, SCID, and
Shwachman-Diamond syndrome [72, 73]. Hemophagocytic
lymphohistiocytosis (HLH) is characterized by multisystem
inflammation, a reactive process resulting from hyperactiva-
tion of macrophages, histiocytes and CD8+ T cells, and ab-
normalities in the function of natural killer cells (NK cells).
The most frequent clinical and laboratorial findings include
fever, splenomegaly, cytopenias, hypertriglyceridemia, and
elevated ferritin [74]. Both Chediak-Higashi and Griscelli
Table VI Warning signs of PIDD for dermatologists
Clinical occurrences PIDD Laboratory test
Eczema Wiskott-Aldrich syndrome (WAS) CBC including platelet number and size
(small sized platelets); CMI, AMI
Hyper IgE syndrome (HIES) Serum IgE, eosinophilia
Specific Scorea
Immunodysregulation, polyendocrinopathy
and enteropathy, X-linked (IPEX)
CMI, ANA, RCP
Coombs, glycemia, and TSH
Severe combined immunodeficiency (SCID),
erythroderma
CMI
Cutaneous lesions byMycobacteria Combined immunodeficiencies CMI
Hyper-IgM syndromes AMI
Mendelian susceptibility to mycobacterial diseases II
Chronic granulomatous diseases (CGD) P
Partial albinism, gray hair Chediak-Higashi syndrome Enlarged cytoplasm granules in blood smear
Griscelli syndrome
Telangiectasias Ataxia-telangiectasia AMI; serum alfa-feto protein
Disseminated warts and molluscum Warts, hypogammaglobulinemia, infections, and
myelokathexis (WHIM) syndrome
AMI, CMI lymphoproliferation assay
Cutaneous herpes infections
Dedicator of cytokinesis 8 (DOCK8) deficiency
Idiopathic CD4 lymphopenia
Fragile hair, conic teeth Ectodermal dysplasia II
Abbreviations : AMI antibody mediated immunity, ANA antinuclear antibodies, CBC complete blood count, CMI cellular mediated immunity, II innate
immunity, P phagocytosis, RCP reactive C protein, TSH thyroid stimulating hormone
a Score for classical Hyper IgE diagnosis [26]
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syndromes present as hemophagocytic, with an accelerated
phase affecting all patients by late childhood. This accelerated
phase is characterized by the infiltration of nonmalignant
lymphoid and histiocytoid cells into the viscera, usually in-
duced by Epstein-Barr virus. Clinical findings include
hepatosplenomegaly, lymphadenopathy, and pancytopenia
[75]. Impaired humoral and cellular immune responses, in-
cluding disturbances in B, T, NK, and dendritic cells, along
with chronic inflammatory autoimmune diseases, recurrent
bacterial infections, and persistent antigenic stimulation, are
speculated to favor carcinogenesis in CVID patients. Lym-
phoma and gastric cancer are the most frequent neoplasms
related to this immunologic defect [76, 77]. The risk of cancer
in PIDD patients mainly takes the form of T cell malignancies
(70-fold and 250-fold increased risks of leukemia and lym-
phoma, respectively), and B cell malignancies are high when
compared with the general population [78]. The Spanish
registry identified that 1.3 % of the 1,069 patients developed
cancer; however, the survey was developed within reference
hospitals [34].
Non-Hodgkin lymphoma and Hodgkin lymphoma are
2 of the most common PIDD-associated malignancies
[79]. A recent large-scale assessment of 1,132 patients
in the PIDD registry of the Australasian Society of
Clinical Immunology and Allergy indicated that this
group had a 1.6-fold excess relative risk of cancer
[80]. The relative risk was significantly increased for
non-Hodgkin lymphoma, leukemia, and stomach cancer
(Table VII).
Conclusions
During recent years, new PIDD have been identified, including
some with susceptibility to specific infectious agents and some
diagnosed only in adulthood. Training specialists to recognize
PIDD is important in order to identify the diverse PIDD pheno-
types. The majority of patients initially present to hospital doc-
tors; therefore, a focus on hospital specialists has been suggested.
Clinical immunologists have an important educational role.
Introducing other specialists and health care workers to the
relevant warning signs will facilitate the early diagnosis of PIDD
in patients, leading to better treatments with less sequelae, or
possible cures.
In this reviewwe have addressed the presentations of PIDD
that are seen by different medical subspecialists. These warn-
ing signs are further influenced by the socioeconomic,
climate-related, and living conditions found in different
regions of the world. A review of warning signs that are
specific to different areas of the world should eventually be
undertaken by a worldwide PIDD community of which
LASID plays an important part.
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Table VII Warning signs of PIDD for hematologists
Clinical occurrences PIDD Laboratory tests
Thrombocytopenia with small-sized platelets Wiskott-Aldrich syndrome (WAS) CBC including platelet number and size
(small sized platelets); CMI, AMIOther symptoms: eczema and recurrent infections
X-linked thrombocytopenia
Autoimmune cytopenias (autoimmune anemia,
thrombocytopenia and neutropenia)
Common variable immunodeficiency AMI, ANA
Other features: recurrent infections
Fever, splenomegaly without evidence of
malignancy, cytopenias
Hemophagocytic lymphohistiocytosis (HLH) CBC, triglycerides, ferritin, EBNA
Lymphadenopathy + Splenomegaly Autoimmune lymphoproliferative disease Increased number of alpha beta double-
negative T cells (CD3 + CD4-CD8-),
ANA, RCP
Excluding neoplasias and infections Apoptosis defects
Quantitative and qualitative defects of
neutrophils (neutropenia and neutrophilia)
Neutropenias P
Chronic granulomatous disease (CGD)
Leukocyte adhesion deficiency Leukocytosis, CD18+ cells
Partial albinism, Chediak-Higashi or Griscelli syndrome Enlarged cytoplasm granules
Abbreviations : AMI antibody mediated immunity, ANA antinuclear antibodies, CBC complete blood count, CMI cellular mediated immunity, EBNA
Epstein-Barr nuclear antigen, P phagocytosis, RCP reactive C protein
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